Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 1110-1117

  Mader, David ^a   Huang, Yan ^a   Wang, Cheng ^a   Fraser, Robert ^a   Issekutz, Andrew C ^a   Stadnyk, Andrew W ^a   Anderson, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENCAPSULATION; EOSINOPHIL; FEMALE; IMMUNITY; IMMUNIZATION; INTRANASAL DRUG ADMINISTRATION; LOEFFLER PNEUMONIA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; EOSINOPHILIA; FEMALE; HN PROTEIN; IMMUNIZATION; LIPOSOMES; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0033990805     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00373-4     Document Type: Article

References (45)

1. Collins P.L., McIntosh K., Chanock R.M. Respiratory syncytial virus. Fields B.N., Knipe D.M., Howley P.M. Fields Virology. 1996;1313-1351 Lippincott-Raven, Philadelphia, NY.
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E. Jr, Collins P.L., Connors M., Karron R.A., Chanock R.M. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:1994;13-36.
3. Walsh E.E., Hruska J.F. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. 47:1983;171-177.
4. Levine S., Klaiber-Franco R., Paradiso P.R. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68:1987;2521-2524.
5. Graham B.S., Henderson G.S., Tang Y-W., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:1993;2032-2040.
6. Alwan W.H., Openshaw P. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine. 11:1993;431-437.
7. Murphy B.R., Sotnikov A., Paradiso P.R., Hildreth S., Jensen A.B., Baggs R.B., Lawrence L., Zubak J.J., Chanock R.M., Beeler J.A. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine. 7:1989;533-540.
8. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., Stahl S., Uhlen M., Nguyen T.N., Binz H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 230:1997;155-166.
9. Srikiatkhachorn A., Braciale T. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71:1997;678-685.
10. Sparer T.E., Matthews S., Hussell T., Rae A.J., Garcia-Barreno B., Melero J.A., Openshaw P.J.M. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1998;1921-1926.
11. Tebbey P.W., Hagen M., Hancock G.E. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1998;1967-1972.
12. Corvaia N., Tournier P., Nguyen T.N., Haeuw J.F., Power U.F., Binz H., Andreoni C. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein BBG2NA, in aluminum hydroxide. J. Infect. Dis. 176:1997;560-569.
13. Hancock G.E., Speelman D.J., Heers K., Bortell E., Smith J., Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:1996;7783-7791.
14. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72:1998;2871-2880.
15. Bembridge G.P., Garcia-Beato R., Lopez J.A., Melero J.A., Taylor G. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J. Immunol. 161:1998;2473-2480.
16. Bastien N., Trudel M., Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 234:1997;118-122.
17. Simard C., Nadon F., Seguin C., Thien N.N., Binz H., Basso J., Laliberte J.F., Trudel M. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. Vaccine. 15:1997;423-432.
18. el Guink N., Kris R., Goodman-Snitkoff G., Small P., Mannino R. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 7:1989;147-151.
19. Gilbert B., Knight C., Alvarez F., Waldrep C., Rodarte J.R., Knight V., Eschenbacher W.L. Tolerance of volunteers to cyclosporin A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 156:1998;1789-1793.
20. Waldrep J.C., Gilbert B.E., Knight C.M., Black M.B., Scherer P.W., Knight V., Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Chest. 111:1997;316-323.
21. Khanna C., Anderson P.M., Hasz D.E., Katsanis E., Neville M., Klausner J.S. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer. 79:1997;1409-1421.
22. Iinuma H., Nerome K., Yoshioka Y., Okinaga K. Characteristics of cytotoxic T lymphocytes directed to influenza virus hemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine. Scand. J. Immunol. 41:1995;1-10.
23. Oxford J.S., Hockley D.J., Heath T.D., Patterson S. The interaction of influenza virus hemagglutinin with phospholipid vesicles: morphological and immunological studies. J. Gen. Virol. 52:1981;329-343.
24. Powers D.C., Manning M.C., Hanscombe P.J., Pietrobon P.J. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. J. Infect. Dis. 172:1995;1103-1107.
25. Lowell G., Kamiski R., VanCott T., Slike B., Kersey K., Zawoznik E., Loomis-Price L., Smith G., Redfield R.R., Amselem S., Birx D.L. Proteosomes, emulosomes and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal and lung IgA and IgG. J. Infect. Dis. 175:1997;292-301.
26. Kramp W., Six H., Kasel J. Postimmunization clearance of liposome entrapped adenovirus type 5 hexon (41321). Proc. Soc. Exp. Biol. Med. 169:1982;135-139.
27. Manesis E.K., Cameron C.H., Gregoriadis G. Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBS Lett. 102:1979;107-111.
28. Epstein M., Morgan A., Finerty S., Randle B., Kirkwood J. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature. 318:1985;287-289.
29. Osiowy C., Horne D., Anderson R. Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin. Diag. Lab. Immunol. 1:1994;670-677.
30. Cherwinski H.M., De Blas A.L. Detection of antigens on nitrocellulose paper immunoblots with monoclonal antibodies. Anal. Biochem. 133:1983;214-219.
31. Kirby C., Gregoriadis G. Dehydration-rehydration vesicles (DRV): a new method for high yield entrapment in liposomes. Bio. Technol. 2:1984;979-984.
32. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of Interleukin-4 (IL-4) and IL-10. J. Virol. 68:1994;5321-5325.
33. Trudel M., Nadon F., Séguin C., Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology. 185:1991;749-757.
34. Simard C., Nadon F., Seguin C., Trudel M. Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. Antiviral Res. 28:1995;303-315.
35. Doherty P.C. Vaccines and cytokine-mediated pathology in RSV infection. Trends Microbiol. 2:1994;148-149.
36. Alwan W.H., Kozlowska W.J., Openshaw P.J.M. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:1994;81-89.
37. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:1996;2852-2860.
38. Ohishi K., Kabeya H., Amanuma H., Onuma M. Induction of bovine leukaemia virus Env-specific Th1 type immunity in mice by vaccination with short synthesized peptide liposome. Vaccine. 14:1996;1143-1148.
39. Walker W., Brewer J.M., Alexander J. Lipid vesicle-entrapped influenza A antigen modulates the influenza A-specific human antibody response in immune reconstituted SCID-human mice. Eur. J. Immunol. 26:1996;1664-1667.
40. Gruber C., Levine S. Respiratory syncytial virus polypeptides IV: the oligosaccharides of the glycoprotein. J. Gen. Virol. 66:1985;417-432.
41. Alexander S., Elder J. Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science. 226:1984;1328-1330.
42. Chanock R.M., Parrott R.H., Connors M., Collins P.L., Murphy B.R. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics. 90:1992;137-143.
43. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson, Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711.
44. De Haan A., Groen G., Prop J., van Rooijen N., Wilschut J. Mucosal immunoadjuvant activity of liposomes: role for alveolar macrophages. Immunology. 89:1996;488-493.
45. Sallenave J.M., Porteous D.J., Haslett C. Gene therapy for lung inflammatory diseases: not so far away? Thorax. 52:1997;742-744.